JACC:高血压发病年龄与心血管疾病风险的相关性研究

2020-06-15 MedSci原创 MedSci原创

高血压发病年龄与心血管疾病(CVD)及全因死亡率的关系尚不明确。本研究的目的旨在评估高血压的发病年龄与CVD及全因死亡率的相关性。

高血压发病年龄与血管疾病(CVD)及全因死亡率的关系尚不明确。本研究的目的旨在评估高血压的发病年龄与CVD及全因死亡率的相关性。

本研究纳入分析了71245名基线水平无高血压和CVD的参与对象,随访期间有20221名对象出现高血压,并为每一位新发高血压患者随机选取一名年龄性别匹配的正常对象作为对照,共19887名对照。经过平均6.5年时间的随访,有1672名患者出现CVD,2008名患者死亡。经过多元分析后发现,高血压的发病年龄越高,不良结局的危险性逐渐减弱。对于高血压发病年龄<45岁的患者,CVD和全因死亡的平均危险比(HR)分别为2.26 (1.19-4.30)和2.59 (1.32-5.07),发病年龄在45-54岁的分别为1.62 (1.24-2.12)和2.12 (1.55-2.90),发病年龄在55-64岁的分别为1.42 (1.12-1.79)和1.30 (1.03-1.62),发病年龄≥65岁的分别是1.33 (1.04-1.69)和1.29 (1.11-1.51)。

研究结果显示,高血压与心血管病和全因死亡率的高风险相关,且与发病年龄越年轻越相关。

原始出处:

Chi W et al.Association of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality.JACC.2020 June.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837846, encodeId=fa10183e84637, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Mar 09 09:07:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854808, encodeId=acc0185480889, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 26 06:07:59 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326656, encodeId=7aaa1326656da, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473234, encodeId=126f14e3234db, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498736, encodeId=b8f71498e3698, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620336, encodeId=41a6162033670, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837846, encodeId=fa10183e84637, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Mar 09 09:07:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854808, encodeId=acc0185480889, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 26 06:07:59 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326656, encodeId=7aaa1326656da, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473234, encodeId=126f14e3234db, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498736, encodeId=b8f71498e3698, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620336, encodeId=41a6162033670, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2021-05-26 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837846, encodeId=fa10183e84637, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Mar 09 09:07:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854808, encodeId=acc0185480889, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 26 06:07:59 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326656, encodeId=7aaa1326656da, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473234, encodeId=126f14e3234db, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498736, encodeId=b8f71498e3698, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620336, encodeId=41a6162033670, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837846, encodeId=fa10183e84637, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Mar 09 09:07:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854808, encodeId=acc0185480889, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 26 06:07:59 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326656, encodeId=7aaa1326656da, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473234, encodeId=126f14e3234db, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498736, encodeId=b8f71498e3698, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620336, encodeId=41a6162033670, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837846, encodeId=fa10183e84637, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Mar 09 09:07:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854808, encodeId=acc0185480889, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 26 06:07:59 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326656, encodeId=7aaa1326656da, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473234, encodeId=126f14e3234db, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498736, encodeId=b8f71498e3698, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620336, encodeId=41a6162033670, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837846, encodeId=fa10183e84637, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Mar 09 09:07:59 CST 2021, time=2021-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854808, encodeId=acc0185480889, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed May 26 06:07:59 CST 2021, time=2021-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326656, encodeId=7aaa1326656da, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473234, encodeId=126f14e3234db, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498736, encodeId=b8f71498e3698, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620336, encodeId=41a6162033670, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Wed Jun 17 05:07:59 CST 2020, time=2020-06-17, status=1, ipAttribution=)]

相关资讯

JACC:肾去神经术在高风险高血压患者中的应用

肾失神经术(RDN)正在研究用于治疗不受控制的高血压,可能是一种对心血管(CV)高风险患者有吸引力的治疗方法。确定基线CV风险是否影响RDN的疗效是很重要的。本研究的目的是评估高风险高血压患者RDN后

盘点:JACC6月第二期研究一览

1. 不同心脏磁共振表现致心律失常性右心室心肌病患者的预后研究

JACC:心脏移植前过渡装置的选择研究

本研究的目的旨在评估临时循环支持心室辅助装置(TCS-VAD)作为心脏移植的过渡存活率要优于体外膜肺氧合(ECMO)。

JACC:血流储备分数的应用可以降低稳定性心绞痛患者的远期死亡风险

冠脉内导丝测量的分流量储备(FFR)为经皮冠脉介入(PCI)手术的决策提供了依据,然而,关于FFR对稳定型心绞痛患者长期临床转归的影响的资料有限。本研究的目的是确定在接受PCI的稳定型心绞痛患者中,F

JACC:射血分数的恢复与年轻心梗患者预后的相关性研究

左室射血分数(EF)的恢复与心梗后远期预后的改善呈相关性,然而,年轻心肌梗死患者的长期预后与EF恢复之间的关系尚未被研究。本研究旨在评估年轻时首次心肌梗死患者的左室收缩功能不全的患病率,并比较恢复EF

JACC:微泡与冠脉搭桥术后患者的预后独立相关

移植血管通畅是冠状动脉搭桥术(CABG)后远期疗效的主要决定因素之一。生物标记物,如果能提示潜在的病理生理机制,则能避免移植失败。微泡(MVs)对中期移植血管通畅的预后价值尚未被证实。本研究的目的是评